Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
| Autor: | David Proudman, Sedge Lucas, Jeffrey Allen, Pallavi Patwardhan, Dave Nellesen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Cost Control Recombinant Fusion Proteins Eltrombopag Pharmaceutical Science Pharmacy Receptors Fc Benzoates Drug Costs chemistry.chemical_compound Young Adult Medicine Humans Romiplostim business.industry Health Policy Middle Aged Thrombocytopenia Immune thrombocytopenia United States Hydrazines chemistry Thrombopoietin Cost-minimization analysis Chronic Disease Pyrazoles Female business medicine.drug |
| Zdroj: | Journal of managed carespecialty pharmacy. 27(10) |
| ISSN: | 2376-1032 |
| Popis: | BACKGROUND: Promacta (eltrombopag; EPAG) and Nplate (romiplostim; ROMI) have not been compared in head-to-head trials for treatment of chronic immune thrombocytopenia (cITP); however, indirect trea... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|